Review: Do we need new antibiotics for treating exacerbations of COPD?

Theraputic Advances in Respiratory Disease

Volumn 1, Issue 1, 2007, Pages 61-76

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

bacteria; chronic bronchitis; colonization; COPD; exacerbations. Introduction; infection

Indexed keywords

ANTIINFECTIVE AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIOXIDANT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; GEMIFLOXACIN; IMMUNOMODULATING AGENT; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; MUCOLYTIC AGENT; OFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIOTROPIUM BROMIDE;

BACTERIAL PNEUMONIA; CHRONIC BRONCHITIS; DRUG DEVELOPMENT; HUMAN; REVIEW; AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BRONCHUS MUCOSA; CHLAMYDIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; STREPTOCOCCUS PNEUMONIAE; VIRAL RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; DRUG DISCOVERY; HUMANS; PNEUMONIA, BACTERIAL;

EID: 48049107364     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465807082692     Document Type: Review

References (92)

1. Aaron, S.D. et al. (2002) Measurment of short-term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 121: 688–696.
2. Adams, S.G. et al. (2000) Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117: 1345–1352.
3. Alat (2001) Grupo de Trabajo de la Asociación Latinoamericana del Tórax. Recomendaciones ALAT sobre exacerbación infecciosa de la EPOC. Arch Bronconeumol 37: 349–357.
4. ALAT work group (2004) Update to the Latin American Thoracic Society (ALAT) recommendations on infectous exacerbations of COPD. Arch Bronconeumol 40: 315–325.
5. Allegra, L. et al. (1991) Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 45: 138–148.
6. Alvarez-Mon, M. et al. (2005) Treatment with the immunomodulator AM3 (Inmunoferon) improves the health-related quality of life of patients with chronic obstructive pulmonary disease. Chest 127: 1212–1218.
7. Anthonisen, N.R. et al. (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106: 196–204.
8. Austrian, R. and Gold, J. (1964) Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intenr Med 60: 759–776.
9. Balgos, A.A. (1998). Guidelinies for the role of antibiotics in acute exacerbations of chronic bronchitis in the Asia-Pacific region: report and recommendations of a consensus group. Med Progress 25: 29–38.
10. Ball, P. and Wilson, R. (1995) The epidemiology and management of chronic bronchitis, the Cinderella of chest diseases: epidemiology and management of chronic bronchitis: a selection of classic papers. Worthing, England: Cambridge Medical Publications, 1995.
11. Ball, P. et al. (1995) Acute infective exacerbations of chronic bronchitis. Quant J Med 88: 61–68.
12. Balter, M.S. et al. (1994) Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians. Can Med Ass J 151(Suppl): 7–23.
13. Balter, M.S. et al. (2003) Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 10 (Suppl B): 3B–32B.
14. Bandi, V. et al. (2001) Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 164: 2114–2119.
15. Blasi, F. et al. (2002) Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance after treatment. Thorax 57: 672–676.
16. Bresser, P. et al. (1997) Persisting Haemophilus influenzae strains induce lower levels of interleukin-6 and interleukin-8 in H292 lung epithelial cells than nonpersisting strains. Eur Respir J 10: 2319–2326.
17. Bresser, P. et al. (2000) Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Am J Respir Crit Care Med 162: 947–952.
18. Burrows, B. and Earle, R.H. (1969) Course and prognosis of chronic obstructive lung disease: a prospective study of 200 patients. New Engl J Med 280: 397–404.
19. Chodosh, S. et al. (1998) The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 27: 730–738.
20. Chodosh, S. et al. (2000) Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 94: 18–27.
21. Cole, P. and Wilson, R. (1989) Host-microbial interrelationships in respiratory infection. Chest 95: 17S–21S.
22. Connors Jr, A.F. et al. (1996) Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: 959–967.
23. Crooks, S.W. et al. (2000) Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 15: 274–280.
24. DeAbate, C.A. et al. (1998) Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. Chest 114: 120–130.
25. Decramer, M. et al. (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 365: 1552–1560.
26. Dewan, N.A. et al. (2000) Acute exacerbation of COPD. Factors associated with poor outcome. Chest 117: 662–671.
27. Doll, H. and Miravitlles, M. (2005) Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature. Pharmacoeconomics 23: 345–363.
28. Donaldson, G.C. et al. (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847–852.
29. Eller, J. et al. (1998) Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 113: 1542–1548.
30. Evans, A.T. et al. (2002) Azithromycin for acute bronchitis: a randomized, double-blind, controlled trial. Lancet 359: 1648–1654.
31. Gompertz, S. et al. (2001) Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 17: 1112–1119.
32. Gottlieb, D.J. et al. (1996) Urinary desmosine excretion in smokers with and without rapid decline of lung function. The Normative Aging Study. Am J Respir Crit Care Med 154: 1290–1295.
33. Grossman, R. et al. (1998) A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113: 131–141.
34. Hill, A.T. et al. (2000) Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 109: 288–295.
35. Jemal, A. et al. (2005) Trends in the leading causes of death in the United States, 1970–2002. J Am Med Assoc 294: 1255–1259.
36. Kanner, R.E. et al. (2001) Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 358–364.
37. Kessler, R. et al. (1999) Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159: 158–164.
38. Kosmas, E.N. et al. (1997) Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 112: 341–347.
39. Lode, H. et al. (2004) Levofloxacin versus clarithromycin in COPD exacerbation: focus on infection-free interval. Eur Respir J 24: 947–953.
40. MacFarlane, J.T. et al. (1993) Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 341: 511–514.
41. Mannino, D.M. et al. (1997) Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiplecause mortality data. Am J Respir Crit Care Med 156: 814–818.
42. Mio, T. et al. (1997) Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 155: 1770–1776.
43. Miravitlles, M. (2002a) Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 9: 191–197.
44. Miravitlles, M. (2002b) Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 20 (Suppl 36): 9s–19s.
45. Miravitlles, M. (2005) Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment. Expert Rev Pharmacoeconomics Outcomes Res 5: 423–435.
46. Miravitlles, M. and Morera, J. (2007) It's time for an etiology-based definition of chronic obstructive pulmonary disease. Respirology 12: 317–319.
47. Miravitlles, M. and Torres, A. (2004a) Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J 24: 896–897.
48. Miravitlles, M. and Torres, A. (2004b) No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest 125: 811–813.
49. Miravitlles, M. et al. (1999) Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 116: 40–46.
50. Miravitlles, M. et al. (2001) Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 17: 928–933.
51. Miravitlles, M. et al. (2002) Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121: 1449–1455.
52. Miravitlles, M. et al. (2003) Pharmacoeconomic study of antibiotic therapy for acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch Bronconeumol 39: 549–553.
53. Miravitlles, M. et al. (2004a) Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax 59: 387–395.
54. Miravitlles, M. et al. (2004b) The effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin Drug Invest 24: 63–72.
55. Miravitlles, M. et al. (2007) Patient's perception of exacerbations of COPD ’ the PERCEIVE study. Respir Med 101: 453–460.
56. Mogulkoc, N. et al. (1999) Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 160: 349–353.
57. Möller, L.V.M. et al. (1998) Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 157: 950–956.
58. Monsó, E. et al. (1995) Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152: 1316–1320.
59. Monsó, E. et al. (1999) Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 13: 338–342.
60. Nouira, S. et al. (2001) Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomized placebo-controlled trial. Lancet 358: 2020–2025.
61. Papi, A. et al. (2006) Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 173: 1114–1121.
62. Patel, I.S. (2002) Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax 57: 759–764.
63. Poole, P.J. and Black, P.N. (2001) Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br Med J 322: 1–6.
64. Prieto, A. et al. (2001) Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med 163: 1578–1583.
65. Puhan, M.A. et al. (2007) Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review. Respir Res 8: 8–30.
66. Ras, G. et al. (1990) The effect of bacterial products on neutrophil migration in vitro. Thorax 45: 276–280.
67. Rohde, G. et al. (2003) Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization: a case-control study. Thorax 58: 37–42.
68. Sachs, A.P.E. et al. (1995) Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 50: 758–763.
69. Saint, S. et al. (1995) Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. J Am Med Assoc 273: 957–960.
70. Scott, S. et al. (2006) COPD exacerbations. 4: Prevention. Thorax 61: 440–447.
71. Seemungal, T.A.R. (2000) Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1608–1613.
72. Seemungal, T.A.R. et al. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1418–1422.
73. Seemungal, T.A.R. et al. (2000) Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 16: 677–683.
74. Seemungal, T. et al. (2001) Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 1618–1623.
75. Sethi, S. (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347: 465–471.
76. Sethi, S. (2007) Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007. Published ahead of print doi: 10.1164/rccm.200703–417OC.
77. Sobradillo, V. et al. (2000) Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 118: 981–989.
78. Soler, N. et al. (1999) Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 14: 1015–1022.
79. Soler, N. et al. (1998) Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157: 1498–1505.
80. Soler, N. et al. (2007) Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 62: 29–35.
81. Spencer, S. and Jones, P.W. (2003) Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58: 589–593.
82. Stanescu, D. et al. (1996) Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophilia. Thorax 51: 267–271.
83. Stockley, R.A. et al. (2000) Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117: 1638–1645.
84. Viglio, S. et al. (2000) MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 15: 1039–1045.
85. White, A.J. et al. (2003) Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58: 680–685.
86. Wilkinson, T.M.A. et al. (2003) Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonay disease. Am J Respir Crit Care Med 167: 1090–1095.
87. Wilson, R. (2001) Bacteria, antibiotics and COPD. Eur Respir J 17: 995–1007.
88. Wilson, R. et al. (1999) Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 44: 501–513.
89. Wilson, R. et al. (2002) A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 24: 639–652.
90. Wilson, R. et al. (2004) Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125: 953–964.
91. Wu, L. et al. (2000) Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162: 1148–1151.
92. Zalacain, R. et al. (1999) Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 13: 343–348.